Safety and efficacy of intravenous colistin in children

Indian Pediatrics

Volumn 52, Issue 2, 2015, Pages 129-130

  Kumar, Poddutoor Preetham ^a   Giri, Swapnil Rameshwar ^a   Shaikh, Farhan A R ^a   Panigrahy, Nalinikant ^a   Chirla, Dinesh ^a  

^a Rainbow Children's Hospital   (India)

Author keywords

Acute kidney injury; Antimicrobial resistance; Colistin

Indexed keywords

COLISTIMETHATE; CREATININE; ANTIINFECTIVE AGENT; COLISTIN; COLISTINMETHANESULFONIC ACID;

ACINETOBACTER; ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; ADOLESCENT; APNEA; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM ISOLATE; CAUSE OF DEATH; CHILD; CHILD SAFETY; CHILDHOOD MORTALITY; CREATININE BLOOD LEVEL; DESCRIPTIVE RESEARCH; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; INFANT; KLEBSIELLA; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; NEWBORN; OBSERVATIONAL STUDY; PREMATURITY; PROSPECTIVE STUDY; PSEUDOMONAS; PSEUDOMONAS INFECTION; SEPSIS; SURVIVAL; TREATMENT DURATION; YERSINIA; YERSINIA INFECTION; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PRESCHOOL CHILD;

ACUTE KIDNEY INJURY; ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COLISTIN; CREATININE; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; SEPSIS;

EID: 84924152696     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-015-0586-1     Document Type: Article

References (13)

1. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt FA, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597–602.
2. Harish BN, Menezes GA, Shekatkar S, Parija SC. Extended spectrum beta-lactamase-producing Klebsiella pneumoniae from blood culture. J Med Microbiol. 2007;56:999–1000.
3. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21:449–65.
4. Tamma PD, Newland JG, Pannaraj PS, Metjian TA, Banerjee R, Gerber JS, et al. The use of intravenous colistimethate sodium among children in the United States: Results from a multicenter case series. Pediatr Infect Dis J. 2012;32:17–22.
5. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistimethate sodium use in children without cystic fibrosis: A systematic review of the literature. Int J Antimicrob Agents. 2009;33:e1–13.
6. Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V, et al. Colistimethate sodium administration to pediatric and neonatal patients. Eur J Pediatr. 2010;169:867–74.
7. Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V. Pediatr Infect Dis J. 2011;30:218–21.
8. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028–35.
9. Libório AB, Branco KMPC, Bezerra CT. Acute kidney injury in neonates: From urine output to new biomarkers. Biomed Res Int. 2014. http://dx.doi.org/10.1155/2014/601568.
10. Kapoor K, Jajoo M, Dublish S, Dabas V, Gupta S, Manchanda V. Intravenou colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients. Pediatr Crit Care Med. 2013;14:e268–72.
11. Rosanova M, Epelbaum C, Noman A, Villasboas M, Alvarez, V, Berberian G, et al. Use of colistimethate sodium in a pediatric burn unit in Argentina. J Burn Care Res. 2009; 30:612–5.
12. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistimethate sodium) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J. 2009; 28:123–7.
13. Goverman J, Weber JM, Keaney TJ, Sheridan RL. Intravenous colistimethate sodium for the treatment of multi-drug resistant, gram-negative infection in the pediatric burn population. J Burn Care Res. 2007; 28:421–6.